-+ 0.00%
-+ 0.00%
-+ 0.00%

Moleculin Announces Data From Phase 2B/3 "MIRACLE" Trial Evaluating Annamycin In Combination With Cytarabine

Benzinga·05/13/2026 12:06:19
Listen to the news

Preliminary blinded CR rate for the first 45 subjects in the trial approximates 30% and represents ~67% improvement vs. standard of care



First 45-subject data unblinding expected before June 30, 2026



Program targets high-unmet-need AML population, including R/R Venetoclax subjects

Recruitment of Part A continues to the target 90 subjects in Q3 2026 with 56 or 62% subjects recruited and randomized